Davis Polk & Wardwell and Conyers Dill & Pearman advised Roivant Sciences Ltd. on the offering. Cooley advised Immunovant on the transaction. Roivant Sciences Ltd. (Nasdaq:ROIV)...
Roivant Sciences’ $200 Million Common Shares Offering
Immunovant’s $75 Million Common Stock Offering
Cooley represented Immunovant, while Latham & Watkins represented the underwriters in the offering. Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for...